Extracellular vesicles derived from breast cancer cells trigger neutrophils to a pro-tumor profile

Breast cancer is the second most common type of cancer in the world and the first most common among women. It is well established the relationship between cancer and inflammation, and neutrophil infiltration has been described in tumors since 1863. Immune system cells, including neutrophils, are recruited by the tumor microenvironment as a site of chronic inflammation and begin to favor tumor growth. The neutrophils present in the tumor site are called tumor-associated neutrophils (TAN) and can present two phenotypes: N1 (antitumor) or N2 (pro-tumor). As an in vitro polarization strategy for TAN, we use extracellular vesicles (EVs) derived from breast tumor cells (MDA-MB-231) compared to the EVs derived from non-tumor epithelial cells (MCF10).